American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Mar 2012
Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease.
The prognostic factors of Mycobacterium avium complex lung disease (MAC-LD) are not clearly defined. ⋯ The first-line treatment regimen was not associated with all-cause mortality. FC or FC+NB disease, BMI less than 18.5 kg/m(2), and anemia were negative prognostic factors for both all-cause and MAC-specific mortality.
-
Am. J. Respir. Crit. Care Med. · Mar 2012
Multicenter StudyDepressive symptoms and impaired physical function after acute lung injury: a 2-year longitudinal study.
Survivors of acute lung injury (ALI) frequently have substantial depressive symptoms and physical impairment, but the longitudinal epidemiology of these conditions remains unclear. ⋯ Incident depressive symptoms and impaired physical function are common and long-lasting during the first 2 years after ALI. Interventions targeting potentially modifiable risk factors (e.g., substantial depressive symptoms in early recovery) should be evaluated to improve ALI survivors' long-term outcomes.
-
Am. J. Respir. Crit. Care Med. · Mar 2012
A mechanistic role for type III IFN-λ1 in asthma exacerbations mediated by human rhinoviruses.
Human rhinoviruses (HRV) are the leading cause of upper respiratory infections and have been postulated to trigger asthma exacerbations. However, whether HRV are detected during crises because upper respiratory infections often accompany asthma attacks, or because they specifically elicit exacerbations, is unclear. Moreover, although several hypotheses have been advanced to explain virus-induced exacerbations, their mechanism remains unclear. ⋯ Our findings suggest that HRV infections in children with asthma are specifically associated with acute wheezing, and that type III IFN-λ(1) responses mediate exacerbations caused by HRV. Modulation of IFN- λ(1) should be studied as a therapeutic target for exacerbations caused by HRV.